Found: 39
Select item for more details and to access through your institution.
Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Amiodarone and Dronedarone Causes Liver Injury with Distinctly Different Clinical Presentations.
- Published in:
- Digestive Diseases & Sciences, 2024, v. 69, n. 4, p. 1479, doi. 10.1007/s10620-023-08251-2
- By:
- Publication type:
- Article
Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative.
- Published in:
- Drug Safety, 2024, v. 47, n. 4, p. 301, doi. 10.1007/s40264-023-01390-5
- By:
- Publication type:
- Article
Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy.
- Published in:
- Drug Safety, 2024, v. 47, n. 4, p. 321, doi. 10.1007/s40264-024-01399-4
- By:
- Publication type:
- Article
Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 2, p. 201, doi. 10.1111/apt.17762
- By:
- Publication type:
- Article
Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Co‐Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver‐Chip for the Study of Drug‐Induced Liver Injury.
- Published in:
- Current Protocols, 2022, v. 2, n. 7, p. 1, doi. 10.1002/cpz1.478
- By:
- Publication type:
- Article
Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.
- Published in:
- Drug Safety, 2021, v. 44, n. 12, p. 1365, doi. 10.1007/s40264-021-01120-9
- By:
- Publication type:
- Article
Deciphering the Dynamic Complexities of the Liver Microenvironment — Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).
- Published in:
- AAPS Journal, 2021, v. 23, n. 5, p. 1, doi. 10.1208/s12248-021-00629-2
- By:
- Publication type:
- Article
A case series analysis of serious exacerbations of viral hepatitis and non‐viral hepatic injuries in tocilizumab‐treated patients.
- Published in:
- Liver International, 2021, v. 41, n. 3, p. 515, doi. 10.1111/liv.14766
- By:
- Publication type:
- Article
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
- Published in:
- Drug Safety, 2020, v. 43, n. 12, p. 1267, doi. 10.1007/s40264-020-00960-1
- By:
- Publication type:
- Article
Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high‐fat diet in the genetically diverse Collaborative Cross mouse model.
- Published in:
- FASEB Journal, 2020, v. 34, n. 6, p. 7773, doi. 10.1096/fj.202000194R
- By:
- Publication type:
- Article
Next‐Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 2, p. 333, doi. 10.1002/cpt.1571
- By:
- Publication type:
- Article
Liver safety assessment in clinical trials of new agents for chronic hepatitis B.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 2, p. 96, doi. 10.1111/jvh.13223
- By:
- Publication type:
- Article
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2020, v. 51, n. 1, p. 90, doi. 10.1111/apt.15579
- By:
- Publication type:
- Article
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 6, p. 702, doi. 10.1111/apt.15153
- By:
- Publication type:
- Article
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
- Published in:
- Liver International, 2018, v. 38, n. 6, p. 976, doi. 10.1111/liv.13746
- By:
- Publication type:
- Article
Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2018, v. 103, n. 3, p. 390, doi. 10.1002/cpt.890
- By:
- Publication type:
- Article
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Data Mining of the US FDA's Adverse Events Reporting System Database to Evaluate Drug-Drug Interactions Associated with Statin-Induced Rhabdomyolysis.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 6, p. 327, doi. 10.1007/s40290-016-0162-6
- By:
- Publication type:
- Article
Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States.
- Published in:
- International Journal of Molecular Sciences, 2016, v. 17, n. 3, p. 331, doi. 10.3390/ijms17030331
- By:
- Publication type:
- Article
The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action.
- Published in:
- Altex, 2014, v. 31, n. 4, p. 500, doi. 10.14573/altex.1401281
- By:
- Publication type:
- Article
Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action.
- Published in:
- Altex, 2014, p. 500, doi. 10.14573/altex.1401281
- By:
- Publication type:
- Article
Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2013, v. 22, n. 8, p. 861, doi. 10.1002/pds.3470
- By:
- Publication type:
- Article
Sodium Phosphate Tablets and Acute Phosphate Nephropathy.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2009, v. 104, n. 8, p. 1903, doi. 10.1038/ajg.2009.342
- By:
- Publication type:
- Article
Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
- Published in:
- Dermatologic Therapy, 2009, v. 22, n. 3, p. 204, doi. 10.1111/j.1529-8019.2009.01233.x
- By:
- Publication type:
- Article
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2009, v. 18, n. 4, p. 301, doi. 10.1002/pds.1711
- By:
- Publication type:
- Article
An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2008, v. 17, n. 11, p. 1068, doi. 10.1002/pds.1643
- By:
- Publication type:
- Article
Informatic Tools and Approaches in Postmarketing Pharmacovigilance Used by FDA.
- Published in:
- AAPS Journal, 2008, v. 10, n. 1, p. 35, doi. 10.1208/s12248-007-9004-5
- By:
- Publication type:
- Article
Brief Communication: Characteristics of Spontaneous Cases of Tuberculosis Associated with Infliximab.
- Published in:
- Annals of Internal Medicine, 2007, v. 147, n. 10, p. 699, doi. 10.7326/0003-4819-147-10-200711200-00006
- By:
- Publication type:
- Article
An observational study of cholecystectomy in patients receiving tegaserod.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Alosetron: Ischemic Colitis and Serious Complications of Constipation.
- Published in:
- 2006
- By:
- Publication type:
- Editorial
Re: Brandt et al. An evidence-based approach to the management of irritable bowel syndrome in North America<sup>1</sup><FN ID="FN1"><NO>1</NO><B>Disclaimer:</B> No direct support was received for this manuscript. The views expressed are those of the authors and do not necessarily represent those of, nor imply endorsement from, the U.S. Food and Drug Administration or the U.S. government.</FN>
- Published in:
- 2003
- By:
- Publication type:
- Letter
A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial.
- Published in:
- 1986
- By:
- Publication type:
- journal article
Treatment of chronic type B hepatitis with multiple ten-day courses of adenine arabinoside monophosphate.
- Published in:
- Journal of Medical Virology, 1985, v. 15, n. 2, p. 121, doi. 10.1002/jmv.1890150204
- By:
- Publication type:
- Article